The Pharmaceuticals and Medical Devices Agency (PMDA) hopes to see Japan grant the world’s first approval for new drugs, Chief Executive Tatsuya Kondo said in an interview with Jiho. The PMDA is set to conduct “leading-edge reviews,” rather than passively…
To read the full story
Related Article
- PMDA Chief Kondo to Step Down after 11 Years in Charge
March 25, 2019
REGULATORY
- Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
- Many Approved AGs Remain Unlisted Despite Final Pre-Reform Opportunity
June 12, 2026
- iPark CEO Calls for National AI Drug Discovery Platform at LDP Hearing
June 12, 2026
- MHLW Official Urges Proper IRB Selection under New GCP Rules
June 12, 2026
- MHLW Panel Weighs Single IRB, DCT Metrics in Core Hospital Overhaul
June 12, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





